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Abstract: The current literature and state of the art on use of botulinum toxin type-A in the 
treatment of glabellar rhytids was reviewed. Botulinum toxin type-A is a safe and effective way 
to manage glabellar rhytids. Mastery of the anatomy of the glabellar region, familiarity with the 
products currently available on the market and judicious dosing results in excellent cosmetic 
results with minimal adverse events.
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Background
Since the early 1970s, botulinum toxin type-A has been used for medical applications. 
In 2002 the US Food and Drug Administration (FDA) granted approval for cosmetic 
use of botulinum toxin type-A (BoTo-A) (Botox®; Botox Cosmetic; Allergan, Irvine, 
CA, USA) in the treatment of glabellar rhytids. In 2009 the FDA approved the second 
BoTo-A (Dysport®; Ipsen Limited, Berkshire, UK) for use in glabellar lines as well. The 
new availability of a similar, competing product reinforces the utility of a contemporary 
review of applications of botulinum toxin type-A in the glabellar brow region.
There are at least 7 subtypes of the neurotoxin produced by the bacterium 
Clostridium botulinum, but type-A is the most commonly used, and the only one 
currently approved for cosmetic use in the United States. Its selection as the primary 
therapeutic neurotoxin is due to early animal studies that demonstrated it was the most 
potent and longest lasting of all subtypes.1
BoTo-A naturally exists as a protein complex, for which an acidic environment is 
necessary for stabilization. Until it enters a neutral pH environment the active toxin 
moiety is not released. Its mechanism of action irreversibly blocks presynaptic release 
of acetylcholine at the neuromuscular junction. The average onset of clinically evident 
action is several days for both Botox and Dysport. This period of onset is related to 
the need for the process of endocytosis of the toxin into the cells of the nerve terminal 
with eventual disruption of the SNAP-25 protein that is responsible for release of ace-
tylcholine into the neuromuscular junction. Paralysis therefore results from blockade 
of the conversion of an electrical signal from the nerves to the chemical signal at the 
neuromuscular junction.1
Recent reports of undesirable distant effects from BoTo-A which can resemble 
botulinum poisoning have surfaced. Symptoms reported include dysarthria, dysphagia, 
loss of bladder control, and difficulty breathing.2 It is important to note, however, that 
these small numbers of reported severe adverse events were in patients receiving very Clinical, Cosmetic and Investigational Dermatology 2010:3 
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large doses for conditions such as large muscle spasticity 
related to cerebral palsy and cervical dystonia.3 There have 
been no reports of distant complications related to cosmetic 
use of BoTo-A in the face.
Preparation, storage 
and comparison
Both Botox and Dysport require reconstitution with inject-
able saline. Botox is packaged in 100 Botox unit sterile vials. 
A single Botox unit is equivalent to the median lethal dose 
(LD50) in mice when given intraperitoneally. Dysport is pack-
aged in both 300 and 500 Dysport unit vials. Units between 
Botox and Dysport are not equivalent and it has been suggested 
that the ratio equivalents of Botox to Dysport range from 1:2.5 
to 1:5.4 Both manufacturers’ recommend using preservative-
free saline with gentle reconstitution utilizing the vacuum in 
the vial to draw in the saline. Aggressive injection of saline 
resulting in foaming could theoretically denature the neuro-
toxin protein complex. For Botox only, in our experience, a 
dilution of 4 mL of saline resulting in 2.5 U per 0.1 mL injec-
tion results in highly reliable, effective and lasting results in 
the treatment of glabellar rhytids. The manufacturers for both 
Botox and Dysport recommend using the reconstituted product 
within four hours although Botox has been shown to be effec-
tive when preserved in a frozen state up to 6 months5 and in 
our experience for up to one month when refrigerated.
Initial reports with Dysport suggest that the while it is as 
efficacious and safe as Botox, the primary potential benefit 
is that a small subset of patients may have a very prolonged 
effect with normal dosage (eg, greater than 6 months).6 The 
main potential drawback is an increase in diffusion of Dys-
port owing to its smaller size (500 to 900 kDa) compared to 
Botox (900 kDa).4
Use in glabellar rhytids
While BoTo-A is used “off-label” (that is, for applications 
not specifically approved by the FDA) in many practices, 
including for treatment of facial rhytids around the eyes or 
from the frontalis muscle, the only approved cosmetic indica-
tion for either Botox or Dysport is in the treatment of glabellar 
rhytids. Carruthers and Carruthers7 noted that patients being 
treated with botulinum toxin for blepharospasm also had the 
added benefit of improved appearance. Several studies since 
have reproduced the safety and efficacy of BoTo-A for the 
treatment of glabellar rhytids.
Mastery of the anatomy of the glabellar complex is 
paramount for treatment of glabellar rhytids with BoTo-A. 
The complex is comprises the bilateral corrugator supercilii 
muscles. Activity of these muscles results in the formation 
of vertical rhytids along the brow. These often resemble a 
number “11” between the heads of the eyebrows. Additionally, 
the procerus muscle is active in the area. Firing of the pro-
cerus results in horizontal rhytids across the radix of the 
nose. Anatomical study has demonstrated that the thickest 
portion of the corrugator muscle is found consistently at the 
medial canthus, but with a significant amount of muscle bulk 
at the midpupillary line. The depth of the corrugator from 
the surface of the skin is constant from medial canthus to 
mid-pupil. There does not appear to be a vertical segment of 
the corrugator nor does there appear to be an anatomically 
distinct depressor supercilii as suggested by other authors as 
being a significant contributor.8,9
Appropriate therapeutic Botox dosing for treatment of 
the glabellar rhytids has been reported as anywhere from 
20 to 50 U over several injection sites. Dose-ranging studies 
for men and women in Botox have been performed and they 
suggest that 40 U total over the area is effective in women and 
the minimum recommended starting dose for men.10,11 Our 
experience has been that approximately 95% of patients in 
our practice have good response and no serious complications 
using only 7.5 U for each corrugator, 5 U medially, 2.5 U 
mid-pupil and 2.5 U into the procerus. There is no need to 
inject the obicularis medially or laterally to successfully treat 
glabellar rhytids as suggested by other authors.7
Thus recommendations for injection (Botox) are as fol-
lows (Figure 1).
Complications
If you have an adverse aesthetic outcome in the use of 
BoTo-A, you can take solace in the knowledge that the 
effects are temporary. If the patient is pleased with the 
outcome, they must repeat injections to sustain an effect; 
however, if a patient experiences any complications they, too, 
are temporary. There are, however, a few more significant 
potential complications directly related to the injections that 
should be reviewed. The severe systemic effects as described 
in the FDA black box warning have not been reported in 
the cosmetic use of Botox or Dysport. The most common 
reported adverse side effect is eyelid ptosis.
Eyelid ptosis is caused by effects of the toxin on the 
upper eyelid levator muscle. This can occur if the toxin is 
directly injected into the muscle or close enough for the 
toxin to diffuse to the levator. Currently the recommenda-
tion is to not inject at or under the brow in the mid-pupil 
line, as this is the area of highest risk. Alpha-adrenergic 
eye drops (apraclonidine) can be used as a mydriatic agent Clinical, Cosmetic and Investigational Dermatology 2010:3 
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if this complication occurs, and can provide temporary 
improvement in eyelid symmetry. The alpha-adrenergic 
medication causes contracture of Mueller’s muscle, located 
just deep to the levator, and can thus improve the ptosis by 
a few millimeters. Allergan’s FDA study for approval of 
cosmetic Botox reported eyelid ptosis at 5.4%; however, 
this significantly drops once the physician’s experience 
increases.12 With the above treatment regimen described 
our complication rate of eyelid ptosis is 0% over the past 
10 years.
Minor complications such as pain, bruising and ery-
thema are related to the needle necessary for injection and 
usually resolve within minutes to a few days (in the case of 
ecchymosis).
BoTo-A products should never be used in patients with 
neuromuscular junction disorders such as myasthenia gravis 
or Lambert-Eaton, and they are not recommended for preg-
nant women.13
Hypersensitivity or allergic reactions have not been 
reported, but resistance to the effect of Botox due to antibody-
mediated immunoresistance to the neurotoxin–protein 
complex has been described. Its prevalence is less than 5%, 
however, and appears to be related to frequency of treatment, 
not duration of the regimen.14
Conclusion
BoTo-A has been proven to be a safe and effective means 
to treat glabellar rhytids. The new addition of Dysport as 
an alternative to Botox requires further experience in its 
application but early studies show promise that it is a viable 
alternative. The few feared systemic complications have 
been reported only when the toxin is used for large muscle 
disorders and in much higher doses than typically used for 
cosmetic indications. Serious complications such as eyelid 
ptosis can be avoided through judicious dosage selection and 
mastery of the underlying muscle anatomy.
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